Home >> NSC348884
Related Products
NSC348884 nucleophosmin inhibitor

Catalog No.B6190
Size Price Stock Qty
5mg
$68.00
In stock
25mg
$208.00
In stock
100mg
$558.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

NSC348884

NSC348884 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

NSC348884 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 81624-55-7 SDF Download SDF
Synonyms N/A
Chemical Name N1,N1,N2,N2-tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine
Canonical SMILES CC1=CC=C2N=C(CN(CC3=NC4=CC=C(C)C=C4N3)CCN(CC5=NC6=CC=C(C)C=C6N5)CC7=NC8=CC=C(C)C=C8N7)NC2=C1
Formula C38H40N10 M.Wt 636.79
Solubility ≥63.7mg/mL in DMSO Storage Store at -20°C
Physical Appearance A solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

IC50: 1.7-4.0 μM for tested cancer cell lines

NSC348884 is a nucleophosmin inhibitor.

Nucleophosmin is identified as a multifunctional nucleolar phosphoprotein, which is dysregulated in human malignancies resulting in anti-apoptosis and differentiation inhibition.

In vitro: NSC348884, which was identified as a putative nucleophosmin small molecular inhibitor, was found to be able to disrupt a hydrophobic pocket that was required for oligomerization, and NSC348884 could also inhibit the cell proliferation in distinct cancer cell lines and disrupt nucleophosmin oligomer formation. Moreover, the treatment of several cancer cell types with NSC348884 could dose-dependently upregulate p53 and also induce apoptosis that correlated with H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage as well as Annexin V. Furthermore, NSC348884 could also synergize doxorubicin cytotoxicity on the viability of cancer cells [1].

In vivo: Previous study showed that the in-vivo intravasation and invasion could be significantly inhibited after the injection of NSC348884 into the tumor-bearing mice. In addition, there was no significant difference in overall cell death that was observed by histology in the treated tumors with the 4-hour brief treatments, indicating that the inhibition seen was specific to migration [2].

Clinical trial: Up to now, NSC348884 is still in the preclinical development stage.

References:
[1] Qi W,Shakalya K,Stejskal A,Goldman A,Beeck S,Cooke L,Mahadevan D.  NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene.2008 Jul 10;27(30):4210-20.
[2] Patsialou A,Wang Y,Lin J,Whitney K,Goswami S,Kenny PA,Condeelis JS.  Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res.2012 Oct 31;14(5):R139.